Has Kamal Sharma, DO received payments from drug or device companies?

Yes. Drug and device makers reported $265,690 in general payments to Kamal Sharma, DO across 497 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kamal Sharma, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kamal Sharma, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kamal Sharma, DO

Hematology & Oncology · Lakeland, FLNPI 1093914988

Payments from drug & device makers

$265,690in general payments, 2019–2025

Across 497 payments — averaging $534.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$58K
Aadi Bioscience, Inc.$53K
Mirati Therapeutics, Inc.$42K
Jazz Pharmaceuticals Inc.$35K
Sanofi$34K
Astrazeneca UK Limited$12K
plus $31K from 54 others

What the payments were for

Consulting fees$23,03562%
Travel & lodging$1,6424%
Food & beverage$11,15130%
Education$1,3444%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	37	$57,925
Aadi Bioscience, Inc.	3	$52,751
Mirati Therapeutics, Inc.	12	$42,277
Jazz Pharmaceuticals Inc.	6	$35,279
Sanofi	16	$34,027
Astrazeneca UK Limited	1	$12,050
E.r. Squibb & Sons, L.L.C.	12	$7,909
Stemline Therapeutics Inc.	14	$7,681
Bristol Myers Squibb	21	$3,614
Johnson & Johnson	26	$2,949
Pfizer	39	$911
Incyte Corporation	19	$756
Seagen Inc.	13	$590
Gilead(2 entities)	20	$484
Merck	19	$445
Daiichi Sankyo Inc.	20	$431
Lilly USA, LLC	13	$426
Astellas Pharma US Inc	9	$423
Tempus AI, Inc	14	$379
Novartis	19	$377
Sobi, Inc	12	$326
Regeneron Healthcare Solutions, Inc.	8	$242
Array Biopharma Inc	11	$241
Bayer	10	$213
Dendreon Pharmaceuticals LLC	5	$203
AbbVie	7	$170
Genentech USA, Inc.	7	$160
Pharmaessentia USA Corporation	5	$147
Pharmacosmos Therapeutics Inc.	7	$142
Puma Biotechnology, Inc.	7	$128
Eisai Inc.	6	$118
Coherus Oncology, Inc.	3	$111
Inari Medical, Inc.	1	$97
Beigene USA, Inc.	5	$90
Progenics Pharmaceuticals, Inc.	1	$85
Takeda Pharmaceuticals U.S.A., Inc.	3	$81
AVEO Pharmaceuticals, Inc.	4	$80
Telix Pharmaceuticals	3	$68
Amgen	3	$64
Tersera Therapeutics LLC	2	$60
Taiho Oncology, Inc.	3	$60
Acrotech Biopharma Inc.	3	$58
Beone Medicines USA, Inc.	2	$58
ADC Therapeutics America, Inc.	2	$57
Agios Pharmaceuticals, Inc.	3	$57
Rigel Pharmaceuticals, Inc.	2	$53
EMD Serono, Inc.	2	$51
Alnylam Pharmaceuticals Inc.	3	$51
Deciphera Pharmaceuticals Inc.	2	$50
Servier Pharmaceuticals LLC	2	$49
Sumitomo Pharma America, Inc.	2	$43
Myovant Sciences Inc.	2	$42
Shield Therapeutics Inc	2	$40
Sun Pharmaceutical Industries Inc.	2	$39
Morphosys, US Inc.	2	$36
Legend Biotech USA Inc.	1	$31
Amneal Pharmaceuticals LLC	1	$28
Pharmacyclics LLC, An Abbvie Company	1	$25
Menarini Silicon Biosystems, Inc.	1	$24
Global Blood Therapeutics, Inc.	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Orserdu$7,372
CALQUENCE$4,281
Revlimid$3,102
IMBRUVICA$2,370
ZEPZELCA$125
PROVENGE$109

How this compares

$265,690 in reported general payments places this provider in the 70th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$316,644

Medicare patients

Services billed

14,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ondansetron Hcl	30	$1,688
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	40	$1,675
Anastrozole	22	$436
Lidocaine-PrilocaineLidocaine/Prilocaine	24	$364
Dexamethasone	19	$363
Hydroxyurea	11	$302
Oxycodone Hcl	16	$290
Methadone Hcl	11	$243
Gabapentin	16	$77
Acyclovir	12	$73
Alprazolam	11	$34

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Lakeland

Carl LandgrenMiami$47.8M
Julio ChavezTampa$16.4M
Steven AttiaJacksonville$13.9M
Santosh NairOrange City$13.5M
Frederick LockeTampa$12.8M
Tarek MekhailOrlando$11.2M
Carlos AlemanyOrlando$10.9M
Thomas GeorgeGainesville$10.3M
Sikander AilawadhiJacksonville$9.8M
Richard KimTampa$8.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →